Bangkok Genomics Innovation PCL (BKK:BKGI) EBIT: ฿49.3 Mil (TTM As of Dec. 2025)

Bangkok Genomics Innovation PCL  (BKK:BKGI) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Bangkok Genomics Innovation PCL's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Bangkok Genomics Innovation PCL's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

where Working Capital is:

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Bangkok Genomics Innovation PCL's Earnings Yield (Joel Greenblatt) % for today is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bangkok Genomics Innovation PCL EBIT Related Terms

The historical data trend for Bangkok Genomics Innovation PCL's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bangkok Genomics Innovation PCL EBIT Chart

Bangkok Genomics Innovation PCL Quarterly Data
	Dec19	Dec20	Dec21	Mar22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25
EBIT	Get a 7-Day Free Trial												13.12	8.65	4.48	7.50	28.66

BKK:BKGI vs TMO, DHR, IDXX: EBIT Comparison

For the Diagnostics & Research subindustry, Bangkok Genomics Innovation PCL's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bangkok Genomics Innovation PCL EV-to-EBIT vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Bangkok Genomics Innovation PCL's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Bangkok Genomics Innovation PCL's EV-to-EBIT falls into.

Bangkok Genomics Innovation PCL EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿49.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bangkok Genomics Innovation PCL Business Description